Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

This Phase II open-label trial (n=15) will study Psilocybin-assisted Existential, Attachment and Relational (PEARL; 25mg) therapy for patients with advanced cancer.

Participants will receive a single high-dose (25 mg) of psilocybin within the context of PEARL therapy.

Conducted by the University Health Network in Toronto, this trial aims to evaluate the feasibility, acceptability, and safety of PEARL therapy. PEARL therapy integrates elements from psilocybin-assisted psychotherapy with individual psychotherapies designed for advanced cancer patients.

The study seeks to reduce psychological and existential distress among participants, contributing to research on the efficacy of psychedelic-assisted therapies.

The outcomes will guide future clinical practices and policy. The trial is expected to run from June 2024 to June 2026.

Topic Palliative Care
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University Health Network Toronto
University Health Network is a public research and teaching hospital network in Toronto. The Nikean Psychedelic Psychotherapy Research Centre was established in 2021.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.